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Neoplasms of the sacrum are relatively uncommon,
representing 1 to 2% of all musculoskeletal tumors.2 They
can be classified as primary or metastatic lesions, the for-
mer being either benign or malignant. The most common
malignancy of the sacrum is metastatic disease, whereas
the most common primary sacral tumor is chordoma.
Other sacral malignant lesions include Ewing sarcoma,
myeloma, osteosarcoma, neurofibrosarcoma, angiosarco-
ma, chondrosarcoma, and rarely lymphoma. Referred pain
in the leg or buttock is the typical presenting symptom of
sacral tumors. Neurological signs are rarely seen, and their
manifestation is often late. We describe two rare cases in
which diffuse large B-cell lymphomas presented as pri-
mary malignant sacral tumors.
CASE REPORTS
Case 1
History. This 52-year-old man presented with a 3-week
history of increasing back pain radiating down his right
leg and testicle. The pain eventually progressed to both
buttocks and legs with numbness and tingling in the
buttocks, posterior thighs, and perineal region. He also ex-
perienced subjective urinary retention but not bowel in-
continence. He denied experiencing fevers, chills, night
sweats, or weight loss. An MR imaging study of his lum-
bar spine performed 1 year before presentation was unre-
markable. His family history was significant; one brother
died at age 59 years of lymphoma.
Examination. The patient was ambulatory and had full
lower-extremity motor strength. He had decreased sensa-
tion to pinprick in the S-1, S-2, and S-3 regions bilateral-
ly. Areflexia was present in both knees and ankles. Toes
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Primary lymphomas of the sacrum are rare tumors, reported only in a few cases in the literature. The authors
describe two patients with diffuse large B-cell lymphomas presenting as a sacral tumor.
In the first case a 52-year-old man presented with progressive back pain, bilateral radicular pain, and saddle block
anesthesia secondary to a lytic, expansile soft-tissue mass. The mass arose from the sacrum and eroded through the
right S-1 to S-4 foramina and extended into the epidural space of the spinal canal. On magnetic resonance imaging,
the sacral mass enhanced homogeneously with Gd. In the second case a 64-year-old man presented with left-sided
radicular pain, paresthesias, and progressive weakness due to a lytic soft-tissue mass in the left sacral ala extending
into the left L-5 and S-1 foramina. Metastatic workup in each patient demonstrated unremarkable findings. In both
cases, an open biopsy procedure was performed after nondiagnostic examination of needle biopsy samples.
Histopathological examination showed evidence consistent with diffuse large B-cell lymphoma in both patients. In the
first case the disease was classified as Stage IAE, and the patient subsequently underwent four cycles of cyclophos-
phamide/doxorubicin/vincristine/prednisone (CHOP)– and rituximab-based chemotherapy followed by consolidation
radiotherapy. In the second case the disease was also classified as Stage IAE, and the patient underwent CHOP-based
chemotherapy and consolidation radiotherapy. In both cases radiography demonstrated a decrease in size of the sacral
lymphomas.
The authors review the clinical, radiological, and histological features of sacral lymphomas. Lymphoma should be
considered in the differential diagnosis of sacral tumors.
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Abbreviations used in this paper: CHOP = cyclophosphamide/
doxorubicin/vincristine/prednisone; CT = computerized tomogra-
phy; MR = magnetic resonance.
were downgoing bilaterally, and clonus was absent. His
rectal tone was normal and a bulbocavernosus reflex was
present. Examination of a postvoid residual sample re-
vealed 240 ml of urine. The serum lactate dehydrogenase
level was found to be slightly elevated at 679.
Lumbosacral CT scanning revealed a large lytic sacral
mass centered at S-2 extending to the upper coccyx with
areas of destructive change (Fig. 1 upper left and right).
An associated presacral mass was also present. Osseous
remodeling and scalloping with enlargement of the right
S2–3 and S3–4 neural foramina observed on CT scans.
The mass extended into the epidural space compressing
the distal thecal sac. Magnetic resonance imaging demon-
strated a large, enhancing, destructive expansile mass in
the right distal sacrum, extending from S-2 to the upper
coccyx (Fig. 1 lower left).
Operation and Pathological Examination. Two fluoro-
scopic biopsy procedures were attempted, but the results
were nondiagnostic. The patient subsequently underwent
a right S2–3 sacral laminectomy and exploration of the
sacral canal for a biopsy and partial resection of the sacral
mass. Pathological examination showed large atypical B
cells consistent with a diffuse large B-cell lymphoma (Fig.
2). Immunohistochemical analysis showed CD-20 (B-cell
marker) and Bcl-6 (germinal center marker). The MIB-1
staining was positive in approximately 70% of the large
atypical B cells.
Postoperative Course and Follow Up. A CT scan of the
patient’s chest, abdomen, and pelvis revealed no adenopa-
thy or metastatic disease. Members of the oncology ser-
vice examined a bone marrow biopsy sample, which was
negative. His disease was classified as Stage IAE (Ann
Arbor Classification3 [Table 1]) with localized disease. He
subsequently underwent six cycles of CHOP- and ritux-
imab-based chemotherapy and radiotherapy. An MR im-
age of the pelvis obtained at 4 months posttreatment re-
vealed a significant decrease in size of the sacral mass
(Fig. 1 lower right). The presacral and epidural compo-
nents of the tumor were no longer present. The tumor re-
mained present within the right sacral ala and the right
S1–2, S2–3, and S3–4 neural foramina. At 9 months MR
imaging demonstrated stable residual disease without evi-
dence of recurrence. Clinically, he remained neurological-
ly intact.
Case 2
History. This 64-year-old man presented with a sever-
al-month history of left sacroiliac pain that radiated into
his left leg. This progressed to increasing pain, numbness,
and weakness. He also noted a mass in his lumbar region
that had been increasing in size. He had difficulty ambu-
lating and used a cane for assistance because of the ex-
treme severity of his pain. He denied experiencing fevers,
chills, night sweats, or weight loss. A melanoma was re-
J. K. Liu, P. Kan, and M. H. Schmidt
2 Neurosurg. Focus / Volume 15 / August, 2003
Fig. 1. Case 1. Neuroimaging studies. Upper Left and Right: Coronal (left) and sagittal (right) lumbosacral CT scans
revealing a large, lytic sacral mass centered at S-2 and extending to the upper coccyx with areas of destructive change
and enlargement of the right S2–3 and S3–4 neural foramina. An associated presacral mass is also present. Lower Left:
Axial Gd-enhanced MR imaging demonstrating the enhancing mass extending into the epidural space and compressing
the distal thecal sac. Lower Left: Postoperative Gd-enhanced MR image of the pelvis obtained at 4 months after chemo-
and radiotherapy, revealing a significant decrease in size of the sacral mass with resolution of the epidural compression.
moved from his left cheek 5 years prior. His family histo-
ry was significant for breast, prostate, and skin cancer. 
Examination. The patient had no palpable lymphaden-
opathy. He exhibited tenderness when the sacrum and left
hip were palpated. There was significant limitation of in-
ternal and external rotation of the left hip due to joint pain
and stiffness. A palpable mass was present in the left sa-
cral region. Motor testing revealed Grade 4/5 strength in
the left hip flexors, quadriceps, and hamstrings. He had
decreased sensation to pinprick in the left S-1 distribution.
His reflexes were normal and his toes were downgoing. 
A CT scan revealed a 6.8 ✁ 3.9–cm lytic soft-tissue
mass centered around the left sacral ala with involvement
anterior and posterior to the left ilium that extended to the
left S-1 sacral foramina and to the left iliopsoas and ilia-
cus (Fig. 3 upper and center). Post myelography CT scan-
ning demonstrated no evidence of thecal compression or
proximal nerve root impingement. Computerized tomog-
raphy scans of his chest, abdomen, and pelvis revealed no
evidence of metastatic disease or adenopathy.
Operation and Pathological Examination. Examination
of a fine-needle aspiration biopsy specimen was nondiag-
nostic. Open-core biopsy procedures were then performed
and diagnostic tissue obtained. Pathological examination
showed a diffuse infiltrate of intermediate-to-large atypi-
cal B-lymphoid cells with a proliferation index of 70%,
consistent with a diffuse large B-cell lymphoma. Immu-
noperoxidase studies showed positivity for CD20 (B-cell
marker) and nuclear expression of Bcl-6 (marker of ger-
minal center derivation). 
Postoperative Course. Members of the oncology ser-
vice examined a bone marrow biopsy sample, which was
negative. Based on these results, his disease was classified
as a Stage IAE with localized disease. The patient sub-
sequently underwent three cycles of CHOP-based che-
motherapy, which was followed by radiotherapy. At 3
months, the patient was ambulating without assistance,
but exhibited a slight limp. The soft-tissue mass in the left
sacrum was no longer palpable. A CT scan obtained at 13
months postoperatively revealed a significant decrease in
size of the left sacral mass (Fig. 3 lower).
DISCUSSION
Sacral tumors constitute a wide range of pathological
entities including primary, metastatic, benign, and malig-
nant conditions.1,2,9–11 In a series of 160 sacral tumors, 82%
were primary and 18% secondary.2 The distribution of pri-
mary tumors was equal between benign (25%), low-grade
(26%), and high-grade malignant tumors (30%). 
Giant cell tumors are the most common benign tumors
of the sacrum. They are usually located in the sacral wing
and tend to expand toward the sacral canal and sacroiliac
joints. Other benign tumors include osteoid osteomas,
osteoblastomas, aneurysmal bone cysts, neurilemmomas,
and ependymomas. Chordomas are the most common
low-grade malignant tumors as well as the most common
primary tumors of the sacrum. Other low-grade malignant
tumors include chondrosarcomas, desmoplastic fibromas,
teratomas, and low-grade osteosarcomas. Among high-
grade malignant tumors, metastatic carcinomas are the
most frequent. Ewing sarcomas, osteosarcomas, plasma-
cytomas, and lymphomas comprise the remainder of
high-grade malignant sacral neoplasms. Clinical presenta-
tion depends on the anatomical location, the direction of
spread, and the biological behavior of the tumor.
Primary lymphoma of bone occurs in fewer than 5%
of cases of non-Hodgkin lymphoma and, histologically, is
almost always diffuse large B-cell lymphoma. The most
common sites of bone involvement are the femur, pelvis,
and vertebral column. Although diffuse large B-cell lym-
phoma is the most frequent type of non-Hodgkin lym-
phoma, representing 40% of all new cases of lymphoma,
the incidence of primary sacral lymphoma is unknown.
Diffuse large B-cell lymphomas are highly invasive in
nature and can cause local compression of neighboring
structures with destruction of bone. Although bone mar-
row involvement is present in only 10 to 20% of patients
initially, its detection is important because of its strong
correlation with later spread to the central nervous system.
Similar to other sacral lesions, referred pain in the leg or
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Fig. 2. Case 1. Photomicrograph showing small, round blue
cells. Additional immunohistochemical studies were positive for
CD-20 and Bcl-6, which were consistent with a diffuse large B-cell
lymphoma (data not shown). H & E, original magnification   400.
TABLE 1
Summary of clinical stages of non-Hodgkin lymphomas
according to the Ann Arbor classification*
Stage Distribution of Disease
I involvement of a single lymph node region (I) or a single extra-
lymphatic organ or site (IE)
II involvement of ≥ 2 lymph node regions ipsilat to diaphragm 
alone (II) or w/ involvement of limited contiguous extralym-
phatic organ or tissue (IIE)
III involvement of lymph node regions on both sides of the dia-
phragm (III), which may include the spleen (IIIS) &/or limit-
ed contiguous extralymphatic organ or site (IIIE, IIIES)
IV multiple or disseminated foci of involvement of ≥ 1 extralym-
phatic organs or tissues w/ or w/o lymphatic involvement
* All stages are further divided on the basis of the absence (A) or presence
(B) of the following systemic symptoms: significant fever, night sweats,
and/or unexplained weight loss of greater than 10% of normal body weight.
buttock is the usual presenting symptom because of nerve
root irritation. The duration of symptoms at the time of
diagnosis varies, depending on the aggressiveness of the
lesion. Patients often have an antalgic posture of the hip
in external rotation, which becomes more pronounced
on flexion. Pain, secondary to bone and/or nerve root in-
volvement, can be a source of significant discomfort. Neu-
rological signs are rarely seen and often manifest late.
Rectal examination often reveals a palpable anterior soft-
tissue mass because sacral tumors have a tendency to
grow into the presacral space.
The Ann Arbor staging system developed for Hodgkin
disease has also been used in staging non-Hodgkin lym-
phomas (Table 1).3 The staging system focuses on the
number of tumor sites (nodal and extranodal), location, and
the presence/absence of systemic systems. Both patients
presented in this report suffered focal extranodal disease
with the absence of systemic symptoms (Stage IAE).
Percutaneous biopsy sampling of sacral lesions is a rea-
sonable first line diagnostic tool. Fine-needle aspiration
biopsy sampling performed using CT scanning, fluoro-
scopic, or ultrasonographic guidance has been reported to
be successful. Gupta, et al.,7 reported a diagnostic rate of
93% in their series of 29 patients with lytic spinal lesions.
The series included three patients with sacral lesions (met-
astatic carcinoma and plasmacytoma). Because there is a
7% rate of false-negative findings, a negative biopsy
result should prompt a repeated biopsy procedure, prefer-
ably using a core or trephine tool. In Case 2, examination
of the initial fine-needle biopsy specimen was nondiag-
nostic, and a subsequent open-core biopsy procedure was
required. An open surgical biopsy procedure may be re-
quired in a small number of patients in whom examination
of a preoperative specimen yielded inconclusive results,
as was demonstrated in Case 1.
The CHOP-based chemotherapy regimen has been the
standard of care for the treatment of diffuse large B-cell
lymphoma. It induces a complete response in 40 to 50%
of patients, with 3-year event-free and overall survival
rates of 30% and 35 to 40%, respectively. Abnormal se-
rum LDH level, poor Ann Arbor staging grade and Zu-
brod performance status, extranodal involvement, and
advanced age are poor prognosticators.12 The authors of a
prospective study demonstrated a complete response rate
of 99% and an overall survival rate of 85% in patients
with limited-stage disease (no systemic symptoms, Ann
Arbor Stage I or II) treated with three cycles of CHOP-
based chemotherapy followed by field radiotherapy.6
Rituximab (Rituxan), a chimeric monoclonal antibody
against the CD20 B-cell antigen, has therapeutic activity
in diffuse large B-cell lymphoma.4,8 Recently, the authors
of a randomized study demonstrated an increase in the
complete response rate and disease-free and overall sur-
vival rate in elderly patients with diffuse large B-cell lym-
phoma who underwent both rituximab- and CHOP-based
chemotherapy compared with those in whom CHOP
chemotherapy alone was performed.5 The addition of rit-
uximab to CHOP chemotherapy significantly reduced the
risk of treatment failure and death. The two patients in our
report received slightly different chemotherapy regimens
because in each case a separate oncologist prescribed the
chemotherapy. The patient in Case 2 underwent three cy-
cles of CHOP chemotherapy followed by radiotherapy,
which is currently the standard of care. At our institution,
some oncologists have added rituximab to the CHOP reg-
imen in some elderly patients (as in our Case 1) because
an increased survival benefit has been shown. Future stud-
ies will determine whether the addition of rituximab to
CHOP chemotherapy will become the standard of care.
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Fig. 3. Case 2. Neuroimaging studies. Upper: Postmyelogra-
phy CT scan revealing destructive osseous changes caused by
the left sacral mass. There is no evidence of thecal compression.
Center: Axial CT scan of the pelvis demonstrating a 6.8 ✁ 3.9–cm
lytic soft-tissue mass centered around the left sacral ala with
involvement anterior and posterior to the left ilium that extends to
the left S-1 sacral foramina and to the left iliopsoas and iliacus.
Lower: Postoperative CT scan obtained at 13 months after chemo-
and radiotherapy, demonstrating a significant decrease in size of
the left sacral mass.
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